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Zhiwei Chen*. AIDS Institute, Li Ka Shing Faculty of Medicine,
The University of Hong Kong, Hong Kong SAR, China
Mucosal vaccination offers great advantage for inducing protec-
tive immune response at the sites of viral transmission. A novel
replication-competent modiﬁed vaccinia Tian Tan (MVTT) is an
attenuated variant of the wild-type VTT, which was historically
used as a smallpox vaccine for millions of people in China. MVTT
was generated through genetic engineering and clonal selection
of VTT and exhibited excellent safety proﬁles for mucosal inoc-
ulation. The spike glycoprotein (S) of SARS-CoV was used as a
test antigen after the S gene was constructed in the identical
genomic location of two live vectors to generate vaccine candi-
dates MVTT-S and MVA-S. A head-to-head comparison has been
conducted in mice for inducing neutralizing antibodies (Nabs)
via mucosal vaccination. Our results indicated that MVTT is su-
perior to MVA for inducing high levels of systemic Nab response
post mucosal vaccination. Moreover, a candidate vaccine MVTT-
SIVgpe, which expresses three major viral structural proteins of
simian immunodeﬁciency virus, has been recently characterized
in vitro. The efﬁcacy of MVTT-SIVgpe will be further evaluated in
a highly pathogenic SIV/Chinese macaque model.
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CS15-01 Can We Prevent Hepatocellular Carcinoma in
Chronic Hepatitis B?
Henry L.Y. Chan*. Department of Medicine and Therapeutics,
The Chinese University of Hong Kong
Hepatitis B virus (HBV) infection is the commonest cause of
hepatocellular carcinoma (HCC) most countries in Asia. After the
launching of the universal vaccination program, the incidence
of childhood HCC has been dramatically reduced in Taiwan. As
HCC in adult commonly develop at the age the 40 to 50 years, it
may take another 20 to 30 years before one can see a signiﬁcant
reduction in incidence of adult HCC.
Clearance of HBsAg is the marker of ultimate viral control in
chronic hepatitis B. If HBsAg clearance occurs before the age
of 50, the prognosis is excellent. However, spontaneous HBsAg
clearance is rare. Peginterferon and oral antiviral agents can
induce HBsAg clearance in about 10% and 5% of patients, respec-
tively. High HBV DNA has been found to associate with higher risk
of HCC. However the data from individual studies on the long
term beneﬁt of interferon or antiviral agent is conﬂicting.
A meta-analysis has been conducted to investigate the beneﬁcial
effect of interferon and antiviral agents (mainly lamivudine) on
HCC. Interferon is associated with an approximate 33% reduction
in risk of HCC. Lamivudine is associated with an approximate 80%
reduction in risk of HCC.
In summary, vaccination can prevent HCC by preventing HBV
infection. HBsAg clearance in an early age can almost prevent
HCC. Interferon and antiviral treatment can reduce the risk but
not completely prevent HCC.
CS15-02 Current Japanese Strategies for Preventing HCC
Development
Yoshiyuki Ueno*. Division of Gastroenterology, Tohoku
University Graduate School of Medicine, Sendai, Japan
In Japan, the death caused by liver disease is still major problems
in health care. Most importantly, the death from liver diseases
exceeds 30,000 cases in Japan. Approximately, nearly 80% of
these death is derived from hepatitis C virus (HCV) related liver
diseases, namely hepatocellular carcinoma (HCC).
Although the incident of HCV infections is decreasing in Japan
due to current screening strategies, the patients with estab-
lished infections have reached their most susceptible stage for
developing HCC. In other words, the Japanese patients with
HCV infection are facing highest risk for developing HCC. The
current preventive strategies for developing HCC includes anti-
viral therapy, namely interferon based regimen. However, the
results of current standard therapy, PEG-interferon plus ribavirin
treatment, is not satisfactory in genotype 1b with high viral
load, which is most commonly observed population in Japan
and US. The recent reports have documented up to 50% of the
patients treated with antiviral therapy eradicated HCV genotype
1b infection. Moreover, the adherence to the antiviral therapy
is poorly tolerated in elderly populations, which is now biggest
patients’ population in Japan. Thus, in Japanese society, the
eradication of HCV itself seems more and more difﬁcult. More-
over, the social beneﬁt regarding antiviral treatment in elderly
patients, especially above 70 years old, has not been established.
The patients in this age have the highest risk for developing HCC
and poorest results after antiviral treatment. Furthermore, these
patients tend to be intolerant to the interferon based treatment.
Adverse effects such as depression are more commonly observed
in these elderly patients. Besides these anti-viral treatments,
so-called maintenance therapies are frequently applied to these
elderly populations. Low-dose interferon monotherapy, oral in-
take of ursodeoxy cholic acids, and phlebotomy are included in
these maintenance therapies. However, the recent results from
HALT-C gave questions about the rational of long-term interferon
monotherapy. Thus, the evidences for preventing HCCs by these
maintenance therapies seem to be weak.
In summary, the Japanese strategies for preventing HCC devel-
opment is; i) eradicate the possible as early as possible since
the adherence to the standard antiviral treatment is poor in
elderly patients with HCV, ii) perform social education for un-
derstanding the natural course of HCV infection to accept the
early eradicative treatment, iii) establish the social supportive
program to receive antiviral therapy (both medical and econom-
ical), and iv) develop interferon free based antiviral treatment
to increase the adherence of antiviral therapy in elderly popula-
tions.
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CS15-04 The Role of Polo-like Kinase 1 as a Therapeutic
Target in Hepatocellular Carcinoma
Seng-Gee Lim*. National University Health System, Singapore
Polo-like kinase 1 (PLK1) plays important roles in the progres-
sion of cell cycle, especially for cells transiting from anaphase
to telophase during mitosis. PLK1 has been found to be over-
expressed in various cancers, and has important prognostic im-
plications.
Methods: PLK1 gene expression was evaluated in Hepatocellular
carcinoma (HCC) and found to be overexpressed frequently in
HCC tissues. Gene silencing technology utilizing short interfering
RNA (siRNA) was subsequently employed to study the potential
of PLK1 to be the therapeutic target in treating HCC. Knockdown
with si-RNA was performed to examine for reduction in cell
proliferation using MTS and BrdU assays, after validating reduced
expression by real-time PCR (RTPCR) and Western Blotting. Con-
ﬁrmation of apoptosis was performed using TUNEL assay, and
subsequent pathway of apoptosis was examined using a caspase-
inhibition assay. Experiments with transplanted tumour cell lines
into nude mice co-cultured with si-RNA against the target gene,
and examining for reduced tumour progression compared to
controls was performed.
Results: Microarray analysis showed the most common over-
